Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
GLP-1 receptor agonists have great therapeutic potential for treating diabetes and obesity
GLP-1 Native GLP-1 reduces adipogenesis via ERK-inhibition, downregulating PPAR , LPL , C/EBP and FABP4 [12, 22, 23, 31]
Image Credit: Edugrafo / Shutterstock In a recent study published in the Journal of the American Heart Association , researchers used nationally representative federal survey data to examine trends in glucagon-like peptide-1 receptor agonist (GLP-1RA) utilization and associated payments between 2017 and 2022
Their findings open up new possibilities for the development of new GLP-1 drugs (RSC
Body composition analysis provides more accurate progress tracking than weight alone
Functionally significant insulin-like growth factor I receptor mutations in centenarians
